{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:01:40Z","timestamp":1768402900098,"version":"3.49.0"},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To evaluate the appropriateness of chemotherapy use at the Oncology Department of the Bugando Medical Centre of Mwanza, Tanzania.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study was an observational prevalence\u2010based study designed to evaluate a single\u2010chemotherapy cycle during a defined time period for a cross\u2010section of patients at varying stages of their clinical history. The sample included 103 consecutive subjects who were treated during January\u2010March 2017 and had at least one previous cycle. Chemotherapy treatment omissions, cycle delays, and dose reductions and their causes were recorded using a standard form that included demographic, anthropometric, and clinical items. The data were analyzed descriptively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 59 males (57.3%) and 44 females (42.7%). Ninety\u2010four patients were aged \u226518\u00a0years. Considering cancer type\/site, there were 23 distinct groups of patients. The recorded number of drugs in the chemotherapy regimens varied between one and five. The median cycle number was three (range: 2\u201011). Sixty\u2010eight (66.0%) patients were treated in a standard fashion. For the remaining, cycle delay and dose reduction were the most common cause for nonstandard treatment. Hematologic toxicity was responsible for the greater part of cycle delays, whereas dose reductions were accounted for by a larger spectrum of causes. Overall, toxicity explained 21\/35 (60.0%) patients receiving nonstandard treatment. The distribution of toxic events was skewed toward grade 1 and grade 2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The observed level of appropriateness of chemotherapy was encouraging. The proportion of patients experiencing severe toxic effects was lower than expected.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.2672","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T12:38:04Z","timestamp":1573648684000},"page":"133-140","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluating the appropriateness of chemotherapy in a low\u2010resource cancer centre in sub\u2010Saharan Africa"],"prefix":"10.1002","volume":"9","author":[{"given":"Patrizia","family":"Serra","sequence":"first","affiliation":[{"name":"Biostatistics and Clinical Trials Unit Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deogratias M.","family":"Katabalo","sequence":"additional","affiliation":[{"name":"Oncology Department Bugando Medical Centre Mwanza Tanzania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nestory","family":"Masalu","sequence":"additional","affiliation":[{"name":"Oncology Department Bugando Medical Centre Mwanza Tanzania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dino","family":"Amadori","sequence":"additional","affiliation":[{"name":"Istituto Oncologico Romagnolo Forl\u00ec Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salustia","family":"Bugingo","sequence":"additional","affiliation":[{"name":"Oncology Department Bugando Medical Centre Mwanza Tanzania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Foca","sequence":"additional","affiliation":[{"name":"Biostatistics and Clinical Trials Unit Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-8538","authenticated-orcid":false,"given":"Sara","family":"Bravaccini","sequence":"additional","affiliation":[{"name":"Gerobiomics Unit, Bioscience Laboratory Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Donati","sequence":"additional","affiliation":[{"name":"Oncology Pharmacy Unit Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6771-8119","authenticated-orcid":false,"given":"Lauro","family":"Bucchi","sequence":"additional","affiliation":[{"name":"Romagna Cancer Registry Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Masini","sequence":"additional","affiliation":[{"name":"Oncology Pharmacy Unit Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,11,13]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70175-X"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61152-X"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-13-304"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00012-7"},{"issue":"1","key":"e_1_2_11_6_1","first-page":"3909","article-title":"Challenges of anticancer chemotherapy in Africa","volume":"15","author":"Ndom P","year":"2008","journal-title":"Can J Urol"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70472-2"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61148-5"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-2903-0"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(03)00296-X"},{"key":"e_1_2_11_11_1","volume-title":"The United Republic of Tanzania Ministry of Health and Social Welfare","author":"National Cancer Control Strategy (NCCS)","year":"2013"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00038-017-0971-8"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-017-0115-z"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/jgo.18.13000"},{"key":"e_1_2_11_15_1","volume-title":"In\u2010Depth Assessment of the Medicines Supply System in Tanzania","author":"Ministry of Health and Social Welfare, Tanzania"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30788-X"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2009.45"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2016.17"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18060639"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2672","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.2672","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T19:23:15Z","timestamp":1694114595000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.2672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,13]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1002\/cam4.2672"],"URL":"https:\/\/doi.org\/10.1002\/cam4.2672","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,13]]},"assertion":[{"value":"2019-09-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}